Anti-Human IL-13 Reference Antibody (Anrukinzumab, RUO) (HW632066)

Name: Anti-Human IL-13 Reference Antibody (Anrukinzumab, RUO)
Brand: abinScience
SKU: HW632066
Price: 176 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HW632066
Description	Research Grade Anrukinzumab (HW632066) is a humanized monoclonal antibody detecting IL13 in ELISA, Bioactivity: FACS, Functional assay, Research in vivo. Suitable for Human. Highlights ●Multi-Application — Validated across multiple applications.
Reactivité des espèces	Human
Applications	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Espèce hôte	Human
Clonalité	Monoclonal
Isotype	IgG1-kappa
Applications testées	WB
Cible	IL-13, IL13, Interleukin-13, NC30
Niveau d'endotoxines	< 10 EU/mg
Pureté	>95% as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	P35225
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4. Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifs	IMA-638, 910649-32-0
Contexte	Interleukin-13 (IL13,NC30,Interleukin-13,IL-13) is a ~15 kDa protein. Cytokine that plays important roles in allergic inflammation and immune response to parasite infection. Synergizes with IL2 in regulating interferon-gamma synthesis. Stimulates B-cell proliferation, and activation of eosinophils, basophils, and mast cells. Plays an important role in controlling IL33 activity by modulating the production of transmembrane and soluble forms of interleukin-1 receptor-like 1/IL1RL1. Displays the capacity to antagonize Th1-driven proinflammatory immune response and downregulates synthesis of many proinflammatory cytokines including IL1, IL6, IL10, IL12 and TNF through a mechanism that partially involves suppression of NF-kappa-B. 1. Minty, A. et al. (1993) Nature 362, 248-50. PMID: 8096327 2. McKenzie, AN. et al. (1993) Proceedings of the National Academy of Sciences of the United States of America 90, 3735-9. PMID: 8097324 3. Defrance, T. et al. (1994) The Journal of experimental medicine 179, 135-43. PMID: 7903680 4. Luttmann, W. et al. (1996) Journal of immunology (Baltimore, Md. : 1950) 157, 1678-83. PMID: 8759755 5. Schnyder, B. et al. (1996) Blood 87, 4286-95. PMID: 8639787 6. Miloux, B. et al. (1997) FEBS letters 401, 163-6. PMID: 9013879 7. Kasaian, MT. et al. (2011) Journal of immunology (Baltimore, Md. : 1950) 187, 561-9. PMID: 21622864
Note	For research use only. Not suitable for clinical or therapeutic use.

Images

Bioactivity

Detects recombinant human IL13 (Cat No.: HW632012) in indirect ELISA.
SDS-PAGE

SDS-PAGE for Research Grade Anrukinzumab.
Western blot

Western blot analysis was performed using anti-IL13 monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human IL13 (Catalog No: HW632012)
Lane 2: negative control